For full year 2026, Dec projected "total revenues to range from $840 million to $870 million, comprised of net product sales, ZURZUVAE collaboration revenues and royalty and licensing revenues." ...

Supernus Pharmaceuticals (NASDAQ:SUPN) reported fourth-quarter and full-year 2025 results on Monday, highlighting record revenue, expanding contributions from its “growth products,” and progress ...

Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year.

Earnings call Supernus posted record 2025 revenues of $719 million, up 27% YoY, with 76% of Q4 revenues from four key growth products. Despite GAAP losses due to Sage acquisition costs, management ...

Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that ...

The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection to treat motor fluctuations in adults with advanced Parkinson’s disease ...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported in Q4 CY2025, with sales up 21.5% year on year to $211.6 million. On the other hand, the company’s full-year revenue ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease. The US FDA this week approved the sale of the treatment, which harnesses ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...